EVis Bioscience AG

EVis Bioscience AG, based in Switzerland, specializes in innovative gene delivery systems, focusing on advanced technologies for targeted gene therapy to address rare genetic diseases. Founded in 2024, EVis Bioscience AG is engaged in developing advanced gene delivery solutions. The company has received EUR 740,000 in funding as of March 2026, supporting its preclinical development programs. There are no mentions of significant pivots or changes in business operations.

The company's headquarters is in Switzerland, but no specific office locations are provided. The founder's history is not available. EVis Bioscience AG specializes in advanced gene delivery systems, offering a suite of innovative technologies aimed at revolutionizing targeted gene therapy. The company's core product, the NanoVector platform, is a patented system enabling non-viral, extrahepatic delivery of small and large nucleic acids, including therapeutic RNAs.

This platform is complemented by its proprietary hemi-fused extracellular vesicles (EVs) and synthetic lipid nanoparticles, facilitating targeted delivery of therapeutic nucleic acids. EVis Bioscience serves a diverse clientele, including pharmaceutical companies and research laboratories, particularly within Europe and North America, focusing on developing targeted therapies for rare genetic diseases. EVis Bioscience generates revenue through various channels, including technology licensing programs and research and development (R&D) collaborations. The company partners with pharmaceutical firms and research institutions to offer access to its hybrid technology for RNA loading into extracellular vesicles, facilitating targeted gene-delivery therapies.

Revenue also stems from recurring income generated through the NanoVector platform's usage in ongoing studies and specialized services, such as the chemical kit for RNA loading and the fluorescent kit for tracking EVs. Transactions typically occur as B2B partnerships, where clients engage EVis Bioscience to support their R&D initiatives or acquire licenses to utilize its innovative technologies. EVis Bioscience AG plans to leverage its recent funding of EUR 740,000 raised in March 2026 to support its growth and advance its preclinical development programs. The company is working on upcoming products that enhance their gene delivery technologies but has not provided specific release dates.

Expansion into new markets is a goal, particularly targeting growth in Europe and North America by 2027.